Mortezaeian Hojjat, Firouzi Ata, Ebrahimi Pouya, Anafje Mohsen, Bashghareh Peyman, Doung Phuoc, Qureshi Shakeel
Cardiovascular Intervention Research Center, Rajaei Cardiovascular Medical and Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, IR, Iran.
Cardiovascular Disease Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Int J Emerg Med. 2024 Aug 29;17(1):102. doi: 10.1186/s12245-024-00702-5.
Percutaneous pulmonary valve implantation (PPVI) is a recognized alternative treatment to surgery for patients with dysfunctional right ventricular outflow tracts. Patient selection is essential to avoid serious complications from attempted treatment, such as rupture or dissection, especially of the calcified outflow tracts. We describe a case with an unexpected rupture of a calcified homograft valve and main pulmonary artery, which was treated successfully by emergency implantation of a self-expanding Venus P-Valve (Venus MedTech, Hangzhou, China) without the need for pre-stenting with a covered stent.
A 13-year-old boy had two previous operations of tetralogy of Fallot, one a total repair and the other a homograft valved conduit for pulmonary regurgitation. He presented with dyspnea and severe right ventricular outflow tract obstruction (RVOTO) and had a calcified outflow tract and main pulmonary artery. In the catheter laboratory, a non-compliant balloon dilation resulted in a contained rupture of the conduit. The patient remained hemodynamically stable, and the rupture was treated with a self-expandable Venus P-Valve without the need for a covered stent combined with a balloon-expandable valve or a further surgical procedure.
Preprocedural evaluation with an inflating balloon is necessary to examine tissue compliance and determine suitability for PPVI. However, this condition is accompanied by a risk of conduit rupture. Risk factors of this complication are calcification and homograft use. These ruptures are mostly controlled with a prophylactic or therapeutic covered stent, with a low rate of requiring surgery. However, there are severe ruptures which lead to hemothorax and death. In the available literature, there was no similar reported case of conduit rupture, which a self-expandable Pulmonary valve stent has managed. It seems that fibrosis and collagen tissue around the heart, formed after open surgeries, can contribute to the control of bleeding in these cases.
CONCLUSION (CLINICAL LEARNING POINT): The suitability of patients for the PPVI procedure should be examined more carefully, specifically patients with homograft and calcification in their conduit. Furthermore, conduit rupture might be manageable with self-expandable artificial pulmonary valves, specifically in previously operated patients, and the applicability of this hypothesis is worth examining in future research.
经皮肺动脉瓣植入术(PPVI)是右心室流出道功能障碍患者手术治疗的一种公认替代疗法。患者选择对于避免尝试治疗引发的严重并发症至关重要,如破裂或夹层,尤其是钙化流出道的此类情况。我们描述了一例钙化同种异体瓣膜和主肺动脉意外破裂的病例,该病例通过紧急植入自膨式Venus P瓣膜(Venus MedTech,中国杭州)成功治疗,无需使用覆膜支架进行预支架植入。
一名13岁男孩曾接受过两次法洛四联症手术,一次是完全修复,另一次是同种异体带瓣管道置换术治疗肺动脉反流。他因呼吸困难和严重右心室流出道梗阻(RVOTO)就诊,其流出道和主肺动脉存在钙化。在导管室,使用非顺应性球囊扩张导致管道局限性破裂。患者血流动力学保持稳定,采用自膨式Venus P瓣膜治疗破裂,无需使用覆膜支架联合球囊扩张瓣膜或进一步手术。
术前使用膨胀球囊进行评估对于检查组织顺应性和确定是否适合PPVI是必要的。然而,这种情况伴有管道破裂风险。该并发症的危险因素是钙化和使用同种异体瓣膜。这些破裂大多通过预防性或治疗性覆膜支架控制,手术需求率较低。然而,也有导致血胸和死亡的严重破裂情况。在现有文献中,没有类似的关于自膨式肺动脉瓣支架成功处理管道破裂的报道病例。似乎心脏周围在开胸手术后形成的纤维化和胶原组织有助于控制这些病例中的出血。
结论(临床学习要点):应更仔细地评估患者是否适合PPVI手术,特别是管道存在同种异体瓣膜和钙化的患者。此外,自膨式人工肺动脉瓣可能可处理管道破裂,特别是在既往接受过手术的患者中,这一假设的适用性值得在未来研究中探讨。